| Literature DB >> 35994111 |
Sophie Neveling1, Alexander Johannes Knippel2, Peter Kozlowski2.
Abstract
PURPOSE: The aim of our study was to investigate spontaneous resolution and postnatal outcome in non-immune hydrops fetalis (NIHF). We specifically studied NIHF cases that occurred without any other anomalies in the prenatal diagnostic workup, defined as isolated NIHF (iNIHF).Entities:
Keywords: Fetal diseases; Functional impairment; Isolated non-immune hydrops fetalis; Long-term follow-up; NIHF; Spontaneous resolution
Year: 2022 PMID: 35994111 PMCID: PMC9395874 DOI: 10.1007/s00404-022-06731-w
Source DB: PubMed Journal: Arch Gynecol Obstet ISSN: 0932-0067 Impact factor: 2.493
Fig. 1Generation of the study group ‘isolated non-immune hydrops fetalis’ (iNIHF)1. iNIHF: isolated non-immune hydrops fetalis; NIHF: non-immune hydrops fetalis.1 Nonimmune hydrops fetalis without any malformations, or other clinically relevant anomalies in prenatal diagnostic workup. 2Diagnostic groups based on the definition by Bellini et al. [3]. 3Lack of clarifying diagnostics due to fetal demise (n = 8) or objection to further diagnostics (n = 19). 4Neither reports on postnatal follow-up until discharge from hospital nor prenatally confirmed positive laboratory diagnosis. 5Fetal demises before second trimester (n = 52), no ultrasound examination after first trimester in our center (n = 4). 6Exclusion due to missing information concerning the development of NIHF
Characteristics of included cases
| Mean GA at first diagnosis (w) | Mean maternal age at first diagnosis (y) | Mean maternal BMI | No | |
|---|---|---|---|---|
| iNIHF | 12.93 | 30.62 | 23.58 | 70 |
| Non-isolated NIHF | 14.62 | 32.96 | 24.24 | 630 |
| Total | 14.45 | 32.72 | 24.16 | 700 |
BMI Body mass index (kilogram/square meter), GA Gestational age, iNIHF isolated non-immune hydrops fetalis, NIHF non-immune hydrops fetalis, w weeks, y years
Spontaneous resolution of iNIHF within pregnancy – Baby-take home rate and GA at first examination, first diagnosis and resolution of hf
| Total no (%) | Demisea no (%) | Baby-take- home no (%) | Mean GA at first ultrasound examination | Mean GA at first diagnosis of hf | Mean GA at complete resolution of hf | Mean intervalb | Mean GA at birth/demise | |
|---|---|---|---|---|---|---|---|---|
| In first trimester | 12 (17.1%) | 12 (21.1%) | 10.60 | 10.77 | 12.45 | 1.68 | 39.24 | |
| In second trimester | 40 (57.1%) | 1 (7.7%) | 39 (68.4%) | 11.62 | 11.65 | 18.58 | 6.93 | 38.88 |
| In third trimester | 2 (2.9%) | 2 (3.5%) | 12.14 | 12.86 | 34.00 | 21.14 | 40.07 | |
GA Gestational age (in weeks), hf Hydrops fetalis, iNIHF isolated non-immune hydrops fetalis
First trimester of pregnancy: GA < 14 + 0 weeks; second trimester: GA 14 + 0–27 + 6 weeks; third trimester: GA > 28 + 0 weeks
aDemise included termination of pregnancy (n = 6), spontaneous abortion (n = 3) and postnatal death (n = 4)
bMean interval between first diagnosis and complete resolution of hydrops fetalis/birth/demise (in weeks)
Individual case survey on anomalies in the long-term development of iNIHF
| Anomalies | Follow-up (years) | Prenatal resolution of NIHF | Non-temporary anomalies | Temporary anomalies and additional mild logopedic, psychosocial and motoric impairmenta | Birth at GA (completed weeks + days) | |
|---|---|---|---|---|---|---|
| 1 | Major anomaly | 14 | Yes | Psychosocial anomalies: aggressive social behavior disorder (U9) | 38 + 3 | |
| 2 | Major anomaly | 13 | Yes | 38 + 5 | ||
| 3 | Minor anomaly | 18 | Yes | Neurodermatitis, bronchial asthma | Logopedic anomalies: sigmatism, dyslalia, mild hearing impairment (U8) | 39 + 5 |
| 4 | Minor anomaly | 16 | Yes | Congenital hip dysplasia, joint pain, Raynaud's disease | 40 + 0 | |
| 5 | Minor anomaly | 12 | Yes | Neurodermatitis | Cryptorchidism (U7) Logopedic anomalies: sigmatism (U9) Psychosocial anomalies: encopresis (U10) | 40 + 1 |
| 6 | Minor anomaly | 11 | Yes | Abnormal posture of a kidney | Umbilical hernia (U7) Logopedic anomalies: dyslalia (U8) Psychosocial anomalies: social anxiety (U8), nocturnal enuresis (U9) | 38 + 6 |
| 7 | Minor anomaly | 11 | Yes | Selective IGA deficiency | 39 + 5 | |
| 8 | Minor anomaly | 11 | Yes | Variants with unclear clinical relevance were found in aCGH analysisc | Suspected syndrome (U1–7) due to combination of hypospadias, cryptorchidism, hemangioma, hypertelorism, examinations of metabolism inconspicuous, overall normal development and growth | 39 + 3 |
| 9 | Minor anomaly | 9 | Yes | Sinus pilonidal (U2–3) Logopedic anomalies: sigmatism (U8) | 40 + 0 | |
| 10 | Minor anomaly | 9 | Yes | Congenital hip dysplasia | Logopedic anomalies: dyslalia (U8) Motoric anomalies: abnormal fine motor skills (U9) | 39 + 2 |
| 11 | Minor anomaly | 8 | Yes | Small palatal cyst (U2–6) Logopedic anomalies: dyslalia (U8) Psychosocial development anomalies (U9) | 38 + 6 | |
| 12 | Minor anomaly | 6 | Yes | 39 + 6 | ||
| 13 | Minor anomaly | 6 | No: Mild pericardial effusion GA 28 + 6 weeks | Cryptorchidism (U7) | 34 + 1 | |
| 14 | Overall inconspicuous development | 18 | Yes | Psychosocial anomalies: dyslexia, emotional instability, obesity (U11) suspicious EEG findings without epileptic seizures (U11) | 39 + 2 | |
| 15 | Overall inconspicuous development | 16 | Yes | Psychosocial anomalies, reduced learning ability (U10–11) | 38 + 5 | |
| 16 | Overall inconspicuous development | 9 | Yes | Logopedic anomalies: sigmatism (U8-9) Motoric anomalies: muscular hypotension (U8) | 37 + 6 | |
| 17 | Overall inconspicuous development | 9 | Yes | Logopedic anomalies: dyslalia (sibilant sounds), obstructive tubal dysfunction (U10) | 41 + 1 | |
| 18 | Overall inconspicuous development | 9 | Yes | Logopedic anomalies: dyslalia (ch-sounds, U9) Motoric anomalies: asymmetric posture (U10-11) | 37 + 6 | |
| 19 | Overall inconspicuous development | 3 | Yes | Motoric anomalies: mild muscular hypotension, over extensibility of joints (U7a) | 40 + 5 | |
GA gestational age
aAge of the child categorized by period of standardized pediatric examination (U1-11) according to German pediatric guidelines (GBA)
U1-2: Perinatal. 0–14 days; U 3–6: Infant. 15 days–12 months; U 7–9: Toddler. 1–5 years; U 10–11: Primary school child. 6–9 years
bResults from whole genome oligonucleotide array comparative genomic hybridization (aCGH) analysis: Duplication on 4q31; heterozygous deletion on 6p12; and an increase of 350 kb in 19q13
cResults from whole genome aCGH analysis: duplication on 4p15
Classification of the study collective—our data compared to systematic reviews and recent original studies
| Group of anomalies | This study 2022 | Review: Bellini 2015 [ | Review: Bellini 2009 [ | Clinical guideline: SMFM 2015 [ | Meng 2019 [ | Laterre 2018 [ | Moreno 2013 [ |
|---|---|---|---|---|---|---|---|
| Isolated/idiopathic % | 10.0 ( | 19.8 | 17.8 | 15–25 | 28.0 | 13.7 | 13.2 |
| Chromosomal % | 65.1 ( | 9 | 13.4 | 7–16 | 19.8 | 32.4 | 28.3 |
| Cardiovascular % | 9.1 ( | 20.1 | 21.7 | 17–35 | 4.1 | 9.8 | 7.5 |
| Infectious % | 4.6 ( | 7 | 6.7 | 5–7 | 2.6 | 7.8 | 7.5 |
| Syndromes % | 2.9 ( | 5.5 | 4.4 | 3–4 | 0.2 | 9.8 | 18.9 |
| Lymphatic % | 1.6 (n = 11) | 15.0 | 5.7 | 5–6 | 7.8 | 13.7 | 5.7 |
| Thoracic % | 1.1 ( | 2.3 | 6.0 | 6 | 1.7 | 2 | 5.7 |
| Urinary tract % | 1.0 ( | 0.9 | 2.3 | 2–3 | 2.9 | 1 | 1.9 |
| Feto-maternal unit % | 0.4 ( | 4.1 | 5.6 | 3–10 | 3.0 | 1 | 3.8 |
| Gastrointestinal % | 0.4 ( | 1.3 | 0.5 | 0.5–4 | 0.7 | 0 | 0 |
| Metabolic % | 0.3 ( | 1.3 | 1.1 | 1–2 | – | 0 | 5.7 |
| Extrathoracic tumor % | 0.3 ( | 0.7 | 0.7 | 2–3 | – | 1 | 0 |
| Hematologic % | 0.3 ( | 9.3 | 10.4 | 4–12 | 28.4 | 7.8 | 0 |
| Miscellaneous % | 2.9 ( | 3.6 | 3.7 | 3–15 | 0.8 | 0 | 1.9 |
| This study provides comprehensive outcome data from a cohort of isolated non-immune hydrops fetalis (iNIHF) in which the most common prenatal course was spontaneous resolution. The data may be helpful in counseling expectant parents about survival chances as well as the spectrum of pediatric anomalies and functional impairments. |